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Abstract This study investigated the outcome of a 5-day
headache-speciﬁc multidisciplinary treatment program
(MTP) and the adherence to treatment recommendations in
295 prospectively recruited consecutive headache patients
[210 migraine, 17 tension-type headache (TTH), 68 combi-
nationheadache,including56medication-overuseheadache
(MOH)].Headachefrequencydecreasedfrom13.4(±8.8)to
8.8 (±8.0) days per month after 12–18 months. Forty-three
percent of the participants fulﬁlled the primary outcome
(reduction of headache frequency of C50%), which was less
likely in patients with combination of migraine and TTH
compared to migraine (OR = 3.136, p = 0.002) or TTH
(OR = 1.029,n.s.).Increasingnumberofheadachedaysper
month(OR = 1.092,p B 0.0001)andadherencetolifestyle
modiﬁcations (OR = 1.269, p = 0.004) predicted primary
outcome. 51 of 56 MOH patients were treated successfully.
Thirty-ﬁve percent of the patients were adherent to phar-
macological prophylaxis, 61% to relaxation therapy, and
72% to aerobic endurance sports. MTP is effective in head-
ache treatment. Adherence to therapy was associated with
better outcome.
Keywords Migraine  Headache  Multidisciplinary
treatment program  Adherence
Introduction
Primary headaches, in particular migraine and tension-
type headache (TTH) cause severe burden of disease and
create high costs in the health care system [1, 2].
Increasing headache frequency in migraine or tension-
type headache leads to chronic headache, which is by
deﬁnition headache on more than 15 days per month [3].
Frequent headache increases the risk of frequent intake of
triptans or analgesics, which may result in medication-
overuse headache (MOH) [3]. Usually MOH is treated by
withdrawal from the overused drugs [4]. Longitudinal
studies in academic headache clinics reported relapse
rates from 30 to 41% 1 year after initial outpatient
withdrawal treatment in MOH [5–8].
Treatment of chronic migraine, TTH, and MOH is chal-
lenging for general practitioners and neurologists in private
practice.Providingpatientswithfrequentorsevereheadaches
with information on the pathophysiology and treatment is
time-consuming and cannot be provided in a setting with a
very limited time budget per patient. Therefore, multidisci-
plinary treatment approaches (MTP) were established during
thepastdecadeinafewacademicheadachecentersaroundthe
world [9, 10]. Education about acute and prophylactic treat-
ment is needed and may improve adherence to pharmaco-
logical as well as to non-pharmacological therapy. The term
adherence is used to describe an active role and collaborative
involvement of the patient in the implementation of a thera-
peutic regime. Compliance refers to the degree to which
patients are obedient to medical treatment recommendations
more generally [11]. Noncompliance and non-adherence are
well-known problems of therapy and potentially result in
treatment failure. Little is known about adherence to pro-
phylactic headache treatment. A recent study reports non-
adherencetomedicalprophylaxisinheadachetherapyinupto
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characteristics nor any of the disease-speciﬁc variables were
signiﬁcantly associated with adherence [12]. Increasing
adherence may result in improved clinical outcome. There-
fore, as a ﬁrst step, we undertook a study to investigate
adherence in patients with difﬁcult-to-treat headaches and its
inﬂuence on headache frequency. We hypothesized that
integrated headache care would lead to reasonable adher-
ence to treatment recommendations and satisfying clinical
outcome.
Methods
This is a prospective observational study evaluating the
outcome of headache patients following the MTP of the
West German Headache Center in the year 2008. Informed
consent was obtained from all patients. The study was
approved by the local ethics committee. Inclusion criteria
were (a) C16 years at the time of MTP and (b) diagnosed
as migraine, TTH (or both) and/or MOH, and (c) adequate
knowledge of German language.
All study participants were seen in the outpatient
headache center prior to MTP by a neurologist who diag-
nosed the headache type according to the ICHD-II criteria
(Headache Classiﬁcation Subcommittee 2004) and col-
lected information about demography and frequency and
intake of acute and preventive drugs. Patients were referred
to the 5-day MTP in case of frequent headache (migraine,
TTH, or both), self-reported high burden of disease and
when MOH was diagnosed.
Setting and concept of the MTP
The West German Headache Center is part of the outpatient
service of the Department of Neurology at the University
Hospital Essen. The center provides medical care for
patients with hard-to-treat headaches referred by neurolo-
gists and headache specialists or their insurance company.
The multidisciplinary team comprises neurologists, behav-
ioral psychologists, physical and sports therapists, headache
nurses and consultants from psychosomatic medicine, psy-
chiatry and dentistry if needed. The majority of patients is
referred back with a treatment concept, while approximately
10% of the patients are referred to the outpatient multidis-
ciplinary day clinic treatment program (MTP). Participation
in MTP was recommended to patients suffering from high
headache frequency, high individual burden of disease,
diagnosed as MOH or difﬁcult to treat primary headaches.
Furthermore, possibility of participation depends on reim-
bursement of treatment costs by the health insurance and the
willingness of the patient to participate. The MTP focusing
on education and treatment is performed in groups of ten
patients visiting the Headache Center for 5 days in a row.
Each day starts with a 60-min lecture on headache education
by a physician. These lessons focus on informing patients
about the symptoms, etiology and pathophysiology of
headaches, treatment options and efﬁcacy and possible
adverse events of acute and prophylactic medication and
correct use of these medications. This is followed by group
sessions with a behavioral psychologist for 90 min every-
day. Psychological group sessions provide behavioral rec-
ommendations and discussions about lifestyle, individual
concepts of headache and its etiology, headache triggers and
patients’ attitude towards them and idea of health and
sickness. In addition, patients have the opportunity to
exchange individual experiences and opinions and learn not
only from the professional staff but also from each other
[13]. Important goals are individual identiﬁcation and
modiﬁcation of trigger factors, stress management and pre-
vention or at least reduction in the number of headache
episodes through pharmacological and psychological inter-
ventions. Psychological training tries to implement different
recommendations on lifestyle modiﬁcation: (1) do not to
exceed 10 medication intake days per month; (2) accept the
headache and do not rebel against it; (3) incorporate more
breaks in daily life and avoid hecticness; (4) pay more
attention to your own needs; (5) establish regular sleep times
all nights in the week; (6) establish regular mealtimes all
days in the week; (7) change more slowly between tension
and relaxation; (8) pay less attention to potential trigger
factors.
Patients perform 60 min of relaxation training (PMR)
led by a psychologist, followed by physical therapy
(60 min) and aerobe ergometer training (60 min) under
guidance of a professional physiotherapist in the afternoon.
During the week, these exercises are performed everyday
by all patients. Subsequently, patients have the opportunity
to test various forms of endurance training (mainly using
sports gym equipment) and ﬁnd out which one is suitable
for them.
In addition to the group sessions, each patient has two
face-to-face appointments with a neurologist (2 9 30 min)
and a psychologist (1 9 60 min). These appointments
focus on individual medical therapy and individual psy-
chosocial background or psychiatric comorbidity.
Study procedures
The questionnaire-based follow-up telephone interviews
were performed 12–18 months (some phone calls had to be
delayed due to poor reachability of some patients) after MTP
by a trained medical student. Patients were interrogated
about adherence to treatment recommendations, reasons for
non-adherence, and headache and medication intake days.
The amount of headache days per month was reported by the
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123patients partially on the basis of their headache diaries.
A reduction in headache frequency (days per month) of
C50% was deﬁned as the primary outcome. This endpoint
was suggested by the IHS [14]. Reduction of headache days
per month, frequency of medication intake to treat headache
attacks, adherence to treatment recommendations, and long-
term success in MOH as well as newly occurring MOH were
secondary outcome parameters.
Statistics
The data gained prior to and after MTP were entered into a
database by double entry and quality checked. Continuous
variables were compared utilizing the Student t test or the
Mann–Whitney U test when variables were not normally
distributed. v
2 tests were used for comparison of categorical
variables. p values below 0.05 (two-tailed) were deﬁned as
signiﬁcant. Binary logistic regression and ANOVA were
computed to determine predictors inﬂuencing primary out-
come, which was deﬁned as a reduction of C50% in head-
ache days per month resulting in odds ratios (OR) with 95%
conﬁdence intervals (CI). We used a stepwise selection
procedure to identify the most important predictors of
positive outcome using a p value of 0.05 as inclusion or
exclusion criteria for the logistic regression. Furthermore,
we decided to compute a second model which was adjusted
for age, gender, number of days with intake of acute med-
ication per month, adherence to pharmacological prophy-
laxis, PMR, and aerobic endurance sports as potential
confounders. Additionally, we computed a binary logistic
regression with the variable headache days per month at
baseline stratiﬁed in six groups (1–5, 6–10, 11–15, 16–20,
21–25, and 26–30 days) to identify the number of headache
days which predicts most for primary outcome. All statisti-
cal analyses were performed with PASW Statistics 18.0.0.
Results
Patient characteristics
In 2008, 3,229 de novo patients were treated in the head-
ache center, of whom 362 (11.2%) visited the MTP, which
was the intended population for this follow-up study.
Thirty-eight patients were lost to follow-up, and 29 were
excluded due to unwillingness to participate (n = 2),
headache diagnoses other than migraine, TTH or MOH
(n = 10), age under 16 years (n = 8), lacking knowledge
of German language (n = 6) and early termination of the
MTP (n = 3). The demographic and the diagnostic char-
acteristics of the included 295 patients are displayed in
Table 1. The excluded 67 patients were characterized and
differed signiﬁcantly in age (drop-outs are on average
4 years younger) and had on average 4 years shorter
duration of headache, whereas no difference was found in
all other baseline data.
The analysis of headache characteristics revealed a
signiﬁcantly (p\0.001) higher headache frequency in
TTH than in migraine patients, whereas the patients suf-
fering from migraine and TTH showed headache frequen-
cies which were in between the two single entities
(Table 2). In a further analysis, patients with additional
MOH had the highest headache frequency (mean 22 days)
and reported analgesic or triptan intake on average on
22 days per month.
Table 1 Demographic and diagnostic characteristics of the study
sample
Demography
N 295
Age (years) 41 ± 12.9
Range 16–76
Gender
Men (%) 33 (11)
Women (%) 262 (89)
Clinical features
Diagnosis
TTH and migraine (%) 68 (23)
Migraine (%) 210 (71)
Without aura (%)
a 217 (78)
With aura (%)
a 61 (22)
Episodic (%)
a 217 (78)
Chronic (%)
a 61 (22)
TTH (%) 17 (6)
Frequent episodic (%) 41 (48)
Chronic (%) 44 (52)
MOH
b (%) 56 (19)
Other headache diagnoses (%) 0 (0)
Headache duration (years)
All, mean (range) 19 (1–62)
TTH, mean (range) 15 (1–50)
Migraine, mean (range) 19 (1–62)
Allocation of headache duration
c
\5 years (%) 27 (9)
5–10 years (%) 76 (26)
[10 years (%) 186 (63)
Headache frequency (days per month), mean (range) 13 (1–30)
Intake frequency of drugs for acute headache episodes
(days per month), mean (range)
9 (0–30)
TTH tension-type headache, MOH medication overuse headache
a Patients suffering from migraine and combination of TTH and
migraine
b Multiple diagnoses possible
c Not available for all patients
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The primary endpoint after MTP, deﬁned as a reduction in
headache frequency C50% at follow-up, was observed in
127/295 patients (43%) and differs between the different
groups of primary headaches. The highest amount of
patients (53%) who reached primary outcome criterion is
found in TTH patients compared to 45% in migraine
patients and 29% in patients who suffered from both
migraine and TTH.
Headache frequency decreased in all patients by 5 days
per month on average. Concerning the absolute reduction
of headache days, patients with TTH improved most
(mean: -10 days per month; p = 0.010) compared to
patients with migraine (mean: -4 days per month;
p\0.0001), and those with migraine and TTH (mean:
-5 days per month; p = 0.009) (Fig. 1). However,
patients with TTH were less likely to reach the primary
endpoint because of the high number of 27 headache days
at baseline. Thirty-ﬁve patients (12%) reported no change
in headache frequency, while 69 patients (23%) showed an
increase in headache days. Changes in headache frequency
are shown in Fig. 1.
In parallel with the reduction of headache days, a
reduction of days with intake of acute medication (anal-
gesics or triptans) from 9 to 5 days per month (p\0.0001)
could be observed (Fig. 2).
Predictors for primary outcome
The binary logistic regression analysis revealed that the
number of headache days per month at baseline (OR =
1.092, 95% CI = 1.034–1.144; p\0.0001) and the number
of implemented lifestyle recommendations (OR = 1.269,
95% CI = 1.079–1.492; p = 0.002) were signiﬁcant pre-
dictors for primary outcome. Compared to patients with the
combination of migraine and TTH, patients with migraine
were more likely to fulﬁll primary outcome (OR = 3.136,
95% CI = 1.517–6.483; p = 0.002) as were patients with
TTH (OR = 1.029, 95% CI = 0.275–3.849; n.s.). The
detailed results of this analysis are shown in Table 3.
The interval between participation in MTP and follow-
up interview was no signiﬁcant predictor for outcome.
Student t tests revealed that patients who fulﬁll primary
outcome had a mean of 16 headache days per month and
implemented six or more lifestyle recommendations, while
patients who did not improve suffered from only 12
headache days per month and implemented less than six
recommendations. Furthermore, we computed a separate
binary logistic regression analysis to determine which
number of headache days per month predicts primary
outcome. We stratiﬁed the headache days per month into
six groups in 5-day intervals, ranging from 1 to 5 days of
headache to 26–30 days. The category of patients with 1–5
Table 2 Headache characteristics of the included patients
Primary headache
diagnosis
Gender
(M/F)
Age
Mean years
(range)
Headache
Duration
(years, range)
Headache frequency
Days/month
(range)
Analgesic/triptan intake
frequency
Days/month (range)
MOH (%)
TTH (n = 17) 7/10 40 (18–67) 13 (1–30) 27 (4–30) 8 (0–30) 3 (18)
Migraine (n = 210) 19/191 42 (16–76) 19 (1–62) 11 (1–30) 9 (0–30) 29 (14)
TTH & Migraine
(n = 68)
7/61 40 (17–70) 20 (1–50) 18 (2–30) 10 (0–30) 12 (18)
TTH tension-type headache, MOH medication overuse headache
13
11
8
7
18
27
14
17
0
5
10
15
20
25
30
35
all diagnoses migraine TTH migraine +
TTH
headache days/month baseline
headache days/month follow-up
***
***
**
**
Fig. 1 Change in number of headache days per month at baseline and
follow-up. Headache days per month (mean ± standard error of
mean) at baseline and at follow-up after 12–18 months. *p\0.05;
**p\0.01; ***p\0.001 (comparison by t tests). TTH tension-type
headache
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123headache days per month was determined as the reference
category. In general, the odds ratios increased with the
number of headache days per month, while patients in the
category 21–25 days have the highest chance of reaching
the primary outcome (OR = 13.667, 95% CI = 2.553–
73.162; p = 0.002).
The MOH was diagnosed in 56 patients at admission to
MTP of whom 30 overused analgesics, 9 overused triptans
and 16 had a combined overuse of analgesics and triptans
while only one patient overused opioids. Fifty-one of the
56 patients (91%) showed long-term success. At the time of
follow-up, ﬁve of these 56 patients still fulﬁlled criteria for
MOH and were therefore classiﬁed as treatment failures
(persistent MOH or relapse). Another eight patients who
had episodic headaches at baseline developed an increase
of headache frequency and were overusing headache
medication at follow-up. Four patient overused analgesics
at follow-up, and eight patients showed a combined over-
use of analgesics and triptans, while only one patient
overused triptans.
Adherence to treatment recommendations
Medical prophylaxis
Patients were asked about their adherence to therapeutic
recommendations. Patients received recommendation on
the following prophylactic drugs: topiramate (n = 88),
betablockers (n = 66), magnesium (n = 34), amitriptyline
(n = 30), ﬂunarizine (n = 16), tizanidine (n = 8), opip-
ramol (n = 6), duloxetine (n = 5), valproate (n = 5),
butterbur (n = 1), and lamotrigine (n = 1). 26 patients
take combinations of those medications. Altogether, 244 of
295 patients were advised to take preventive medication, of
whom 22 (9%) did not ﬁll the initial prescription at all.
Ninety-six patients (39%) followed the recommendation
for a limited time (mean 5 months), of whom 13 (5%)
received the recommendation to terminate prophylaxis
after a mean period of 8 months after MTP. Eighty-six
patients (35%) followed the prescription at least until the
telephone interview. The remaining 40 patients (16%)
changed medication. The reasons for changes or termina-
tion are shown in Table 4.
Progressive muscle relaxation, aerobic endurance sports,
and lifestyle recommendations
All patients were instructed in progressive muscle relaxa-
tion (PMR) during MTP, of whom 59 patients (20%) never
performed PMR during follow-up. Fifty-six (19%) patients
executed PMR for 3 months on average, and 180 (61%)
patients still performed PMR on a regular basis at the time
of the telephone interview. On average, patients practiced
PMR on 3 days per week.
Forty-ﬁve (15%) patients discontinued aerobic endur-
ance sports after MTP; 38 (13%) patients continued for
6 moths on average, and 212 (72%) patients strictly fol-
lowed the recommendation. Patients practiced aerobic
endurance sports on 3 days per week on average as
recommended.
Furthermore, patients received eight recommendations
to change their lifestyle. Fifty-six percent of the patients
implemented at least six recommendations. Adherence to
more than ﬁve recommendations was associated with a
signiﬁcant reduction in headache frequency and the pri-
mary endpoint of C50% reduction of headache days per
month. In a multivariate analysis, the strongest predictor
for headache reduction was implementation of the lifestyle
modiﬁcation to ‘‘accept the headache and do not rebel
against it’’.
Patients who did not fulﬁll primary outcome criterion
were less adherent to medical prophylaxis (33.3 vs. 35.4%,
n.s.), PMR (60.7 vs. 61.4%, n.s.), aerobic endurance sports
(69.6 vs. 74.8%, n.s.), and lifestyle modiﬁcation (48.8 vs.
64.6%, p = 0.009) than those patients who showed a
reduction of C50% in headache days per month.
To determine which combinations of implementation of
the various recommendations were predictors for primary
outcome, we computed a variance analysis (ANOVA)
containing the factors ‘‘adherence to pharmacological
10
8
9 9
7
4
5 5
0
2
4
6
8
10
12
all diagnoses migraine TTH migraine + TTH
intake days/month baseline
intake days/month follow-up
***
*
**
***
Fig. 2 Change in acute medication intake frequency at baseline and
follow-up. Intake days of acute medication (mean ± standard error of
mean) at baseline and at follow-up after 12–18 months. *p\0.05;
**p\0.01; ***p\0.001 (comparisons of means by t tests). TTH
tension-type headache
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123therapy’’, ‘‘adherence to PMR’’, ‘‘adherence to aerobic
endurance sports’’, and ‘‘adherence to lifestyle recom-
mendations’’. Most of the combinations including the non-
pharmacological measures showed signiﬁcant effect on
primary outcome while the exclusive pharmacological
therapy had no signiﬁcant inﬂuence (p = 0.943) on the
primary endpoint.
Patients were asked which recommendations (multi-
ple answers possible) were considered as most helpful in
reducing headache frequency. 57% of the patients
regarded the advice to change their daily behavior as the
most important advice resulting in improvement of
headache.
Discussion
Our study demonstrates that an outpatient MTP is effective
in treating patients with frequent migraine, TTH, and MOH
and results in over-all satisfying adherence to relaxation
training, aerobic endurance sports, and implementation of
lifestyle recommendations. Forty-three percent of all
patients reached the primary endpoint of a C50% reduction
of headache days per month. Therefore, MTP was effective
in reducing both headache days (on average -5 days/
month) and medication intake (on average -4 days/
month). This is notable regarding the fact that more chronic
and severely disabled patients were included in the MTP
and patients with 21–25 headaches days per month showed
the most favorable outcome. In addition to headache fre-
quency and headache diagnosis, adherence to treatment
recommendations had a signiﬁcant impact on headache
frequency. Adherence to more than ﬁve lifestyle recom-
mendations was associated with a signiﬁcant reduction in
headache frequency. Lifestyle recommendations are obvi-
ously an important element of the behavioral treatment
concept. The co-occurrence of migraine and TTH was a
negative predictor regarding the reduction of headache
days.
In recent years, different multidisciplinary treatment
programs were established, and their effectiveness was
evaluated. Harpole et al. [13] performed a prospective
analysis of MTP for patients with migraine, TTH, MOH,
cluster headache, and other headache entities involving
headache specialists, psychologists and primary care physi-
cians. They observed a reduction of 21.2 points in MIDAS
after 6 months, including a reduction of 14.5 headache days
on average within 3 months. The percentage of patients with
a reduction of at least 50% in headache frequency was not
calculated [13]. An MTP consisting of repeated appoint-
ments with a headache specialist, physical therapists, psy-
chologists and headache nurses for patients with migraine,
TTH, cluster headache, MOH and posttraumatic headache
was analyzed prospectively by Zeeberg et al. [15]i n
Table 3 Association of primary outcome of MTP and headache diagnosis, headache days before training and implementation of lifestyle
recommendations
Covariates Unadjusted OR (95% CI) p value Adjusted OR (95% CI) p value
Primary headache diagnosis
Migraine 2.867 (1.437–5.719) 0.003 3.136 (1.517–6.483) 0.002
TTH 1.303 (0.404–4.206) 0.658 1.029 (0.275–3.849) 0.966
Both 1.00 (reference) 1.00 (reference)
Headache days per month before MTP 1.076 (1.039–1.114) <0.0001 1.092 (1.043–1.144) <0.0001
Number of implemented lifestyle recommendations 1.272 (1.087–1.488) 0.003 1.269 (1.079–1.492) 0.004
Odds ratios (95% CI) of primary outcome (C50% reduction in headache frequency) were computed using logistic regressions adjusted for age,
gender, years of suffering from headache, adherence to pharmacological prophylaxis, adherence to PMR, adherence to aerobic endurance sports,
and intake days of acute medication. Signiﬁcant p values are presented in bold. p value was\0.0001 for both models
Table 4 Reasons for non-adherence to pharmacological prophylaxis
Reason Number of patients
(%
a)
Ineffectiveness 19 (12.8)
Side effects 41 (27.6)
Fear of side effects 2 (1.4)
Pregnancy 4 (2.7)
Physician’s advice at MTP 13 (8.8)
Denial of daily medication intake 6 (4.1)
General non-compliance 14 (9.5)
Discontinuation 6 (9.5)
No further need because of improvement 9 (6.1)
Preference of non-pharmacological approaches 4 (2.7)
Contraindications 1 (0.7)
Advice of another person (change/termination of
prophylaxis)
b
47 (31.8) (40/7)
Not speciﬁed 8 (5.4)
a Percentage of patients who did not ingest prescribed prophylaxis
until follow-up; multiple answers were possible
b Advice of another person: after MTP, e.g., general practitioner,
neurologist in private practice, physician in West German Headache
Center; main reasons for change or termination were side effects
(19%) and ineffectiveness (17%)
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123Denmark. A signiﬁcant reduction in headache days was
observed in all diagnostic groups except for posttraumatic
headache after a mean period of 7.8 months. Lang et al. [16]
compared the effectiveness of standard headache treatment
in primary health care with two intervention groups: the ﬁrst
group received standard treatment from specially trained
neurologists in private practice; the second group was trea-
ted in a 20-h outpatient MTP at the University Pain Center.
The multidisciplinary program did not outperform conven-
tional primary care in the 6-month follow-up [16]. Later on,
the same researchers compared the results to a 96-h MTP. At
follow-up (after 22 weeks), 60% of the TTH patients and
*58% of the patients suffering from migraine achieved
C50% reduction in headache days (estimated from ﬁgures in
the publication). The more favorable outcome compared to
our data may be a result of the 2.7 times longer intervention
and the shorter follow-up period (5.5 vs. 12–18 months)
[17]. Jensen et al. [9] report outcome data of MOH in a
multidisciplinary headache center. At admission, the patients
suffered from 27.6 headache days/month, at time of follow-
up 14 headache days/month were reported. Magnusson et al.
[18] compared pharmacological therapy to a multidisci-
plinary treatment program for patients with transformed
migraine and MOH in a controlled prospective study. Sev-
eral treatment approaches (for example self-management
group, relaxation group, exercise group) were offered to the
patients. After a mean observation period of 11.6 weeks
(2–22), 35% of the patients achieved a reduction of C25% in
headache days per month. The headache intensity was
decreased by 25% in 23% of the patients. Summarizing the
published data, there is a lack of well-designed studies
comparing conventional treatment with MTP. However,
available data suggest that an MTP may improve headache
care, while efﬁcacy may depend on an adequate duration of
these programs. MTP of 20 or less hours may not be long
enough. The Essen MTP for headache patients has duration
of 36 h in 5 days. A 36-h program can be offered during
1 week, reducing costs compared to longer treatment pro-
grams or inpatient treatment.
The reduction of headache days after MTP is clinically
relevant. Only ﬁve patients showed a relapse of MOH
(11.2%) compared to relapse rates between 30 and 41%
after outpatient withdrawal [5–8]. Overuse of acute medi-
cation is responsible for the development or maintenance
of chronic daily headache (CDH) and successful detoxiﬁ-
cation results in a 70% return to an episodic pattern of
migraine [19]. This supports our psychological and edu-
cational concept focusing on MOH, which showed efﬁcacy
in a recently published randomized trial in behavioral
management sessions as well as in so-called bibliotherapy
[20].
Our therapeutic concept focuses on self-efﬁcacy and
implementation of the treatment recommendations in daily
life. This includes motivating patients to continue aerobic
endurance sports and PMR at home. Therefore, our results
indicate that higher adherence to a combination of behav-
ioral recommendations and implementation of aerobic
endurance sports and PMR is the most effective treatment.
The prophylactic effect of relaxation training in headache
treatment is already proven in several studies [21–23]. We
also observed effectiveness of aerobic endurance sports even
though the level of evidence coming from clinical trials is
still weak [24, 25]. Adherence to PMR and aerobic endur-
ance sports was better than to medical prophylaxis. Adher-
ence to prophylactic treatment is a known problem in
headache care, and factors inﬂuencing adherence to treat-
ment in headache prophylaxis are still unclear and under
debate [11, 12]. The unsatisfying adherence to medical
treatment is a result of side effects and the general wish of
headache patients ‘not to take a permanent medication,’
which was also found in 40% of the patients in other tertiary
headache centers [26]. Thirty-ﬁve percent of our patients
followed the recommendation to take prophylactic medica-
tion. This result is poorer than that achieved by Zeeberg
et al. [15], whose patients show higher adherence. Thirty-
nine percent of the non-MOH patients and even in the group
of MOH patients took their prescribed prophylactic medi-
cation. This may be due to the shorter period of follow-up of
7.8 months compared to our period of 12–18 months. The
non-adherence of our patients was explored in more detail.
Main reasons for non-adherence to pharmacological pro-
phylaxis were ineffectiveness and side effects. In addition,
anxiety of side effects, the denial of daily medication intake,
and general non-compliance were reasons for non-adher-
ence. General non-compliance was reﬂected in only sporadic
intake and in doubts based on the original indications for the
drugs (e.g., depression, hypertension or epilepsy). This was
surprising because patients were given information on
pharmacological prophylaxis. Increasing adherence may
result in improved clinical outcome even though the effects
from different studies were inconsistent. Increasing the
effectiveness of adherence might have more substantial
impact on clinical outcome than improvement in speciﬁc
medical treatments [27]. Non-adherence to treatment rec-
ommendations becomes apparent in not ﬁlling the initial
prescription in 11%, termination of prophylactic regimen in
25–50%, and disregard of lifestyle modiﬁcations in 22–85%
[11]. However, interventional studies on adherence in
headache patients are missing.
We conclude that there is still a need to improve adher-
ence to pharmacological recommendations by informing
patients in more detail, in particular about adverse events and
how to handle them. Our impression is that in the long run,
behavioral modiﬁcations may be more useful than medical
prophylaxis. Our patients reported that learning about head-
ache etiology, pathophysiology, and non-pharmacological
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123coping strategies as well as getting in contact with other
headache patients (to share experiences and coping strategies
and to be not left alone with the disease) were important.
Even patients without reduction in headache frequency
reported that visiting our MTP reduced their burden of dis-
ease because they learned how to handle headache in a more
effective way. This may lead to reduction in medication
intake days and lower headache-related disability as a
consequence.
A methodological strength of our study is the prospec-
tive design and the long follow-up (12–18 months). This is
important for testing sustained effects and may help dis-
tinguish between short-time effects (which were measured
by most of the other studies) and long-lasting results and
sustained changes in behavior.
The major limitation is a lack of control condition, e.g.,
simple advice, which was shown as effective in therapy of
MOH in a population-based study by Grande et al. Notably,
only two of 109, respectively, 18 of 80 patients used pro-
phylactic medication [28]. Boe et al. [29] compared therapy
of MOH patients by primary care physicians and neurolo-
gists with interest in headache and found no differences in
treatment outcome. However, the patients in these two
studies cannot be compared to patients treated in a tertiary
headache center since these patients may have a higher
burden of disease as well as several unsuccessful treatments
before. Future studies should focus on treatment in MTP or
rehabilitation therapy should use controlled designs, even
though blinding is not possible. Also a setting comparing
pharmacological and non-pharmacological prophylaxis was
not possible as our concept of MTP focuses on the multi-
disciplinary approach to provide best care to all patients.
Some other limitations of the study must be mentioned.
This was a non-randomized, open study. Patient selection
led to the typical bias of a tertiary headache center taking
care of severely affected and chronic headache patients.
Selection criteria for admission to MTP may lead to another
bias. However, this cannot be inﬂuenced by the authors.
It has to be assumed that these patients are highly motivated.
All our patients were classiﬁed according ICHD-II. Unlike
Zeeberg et al. [15], we did not use prospective diaries in this
study. However, future studies focusing on this topic should
use prospective headache diaries and should include
assessments for measurement of psychiatric comorbidity
(especially depression and anxiety disorder) as these dis-
eases may inﬂuence headache frequency as well as adher-
ence to treatment recommendations.
Conclusion
The MTP seems to be an effective approach in the treat-
ment of frequent migraine, TTH, and MOH. However,
a prospective, controlled randomized trial comparing
standard treatment to MTP as part of managed care is
needed for producing a real proof of effectiveness.
Adherence to non-pharmacological and behavioral treat-
ment recommendations was associated with a better out-
come. Therefore, long-term treatment should focus on
adherence to therapy as well as on medical information
about headache diagnosis and treatment.
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